Is Mounjaro Good? What the Clinical Evidence Actually Shows

What the trial results tell us about how good Mounjaro actually is

The clearest way to answer this is to start where the regulators did: the SURMOUNT clinical programme. SURMOUNT-1, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks. At the 15mg maintenance dose, average body-weight reduction was around 20–21%. At 10mg, around 19%. Even at the lower 5mg dose, participants lost roughly 15% on average. These are not cherry-picked figures; they are the headline results from a large, randomised, placebo-controlled trial submitted to regulators on both sides of the Atlantic.

NICE reviewed that evidence before recommending tirzepatide in technology appraisal TA1026, published in December 2024. Its independent committee concluded the medicine was both clinically effective and cost-effective enough to recommend for NHS use. That independent appraisal process is arguably the most rigorous filter a medicine goes through in the UK — so "NICE-approved" carries real weight.

In the SURMOUNT-5 head-to-head trial (2025), tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. A question our prescribers hear most weeks is whether one medicine is simply better than the other. The honest answer is that the comparison is more nuanced than the headlines suggest, how good a medicine is depends on individual tolerability, comorbidities, and what outcomes matter most to the person taking it.

How good Mounjaro is at what it is actually licensed to do

Mounjaro is licensed in the UK for weight management alongside a reduced-calorie diet and increased physical activity, in adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The licence was granted on the basis of the SURMOUNT data, meaning the MHRA's medical assessors were satisfied it does what it claims to do.

It works by activating two receptors involved in appetite regulation and blood-sugar control (GIP and GLP-1) slowing gastric emptying and increasing the sensation of fullness. More detail on the mechanism is covered on the tirzepatide overview page. The practical effect most people report is that food simply becomes less preoccupying. Portions feel adequate sooner. That shift in appetite is biological, not willpower, and it is why the clinical results look so different from conventional dieting studies.

For people asking specifically how good Mounjaro is for weight loss, the short answer is: it is currently the most effective weight-loss medicine licensed in the UK. Whether those results translate to your own situation is what a clinical assessment is designed to establish.

Side effects and safety: part of a complete answer

No honest assessment of how good a medicine is can skip the safety picture. The most common side effects reported in trials and in real-world use are gastrointestinal: nausea, loose stools, constipation, indigestion and, for some people, vomiting. These are broadly predictable in timing (they tend to cluster around the start of treatment and around each dose increase) and they often settle within a week or two as the body adjusts.

Treatment starts at 2.5mg. That first pen's job is to let your system acclimatise before any therapeutic dose is reached; titration is gradual and guided by the prescriber. Most people who stop early do so in the first few weeks, which is worth knowing before you start.

More serious but less common reactions include acute pancreatitis. The NHS's patient information for tirzepatide describes the symptoms to watch for: severe, persistent stomach pain that may spread to the back, with or without vomiting. This warrants urgent medical attention. Gallbladder problems, dehydration from prolonged GI illness, and injection-site reactions are also listed in the SmPC. The medicine carries a Black Triangle (▼) designation, meaning the MHRA requests additional reporting of suspected side effects, you can do that at any time via the Yellow Card scheme.

Mounjaro is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for use in under-18s. These are absolute points, not areas for negotiation.

Putting the evidence in context before you decide

The evidence says Mounjaro is, by clinical measures, a highly effective medicine for weight management in appropriate adults. It is not good for everyone. People with a history of medullary thyroid carcinoma or MEN2, certain gastrointestinal conditions, or those taking medicines that interact with it may not be suitable candidates. The range of weight-loss treatment options is worth understanding if you are still at the stage of comparing approaches.

Cost is a practical consideration too. If you want a clear picture of what private treatment involves financially, the Mounjaro cost guide covers what private prices have looked like since Eli Lilly revised UK list pricing in September 2025, and what to watch for when comparing providers. Patients based in the South West who are weighing up local access can find area-specific information on our Mounjaro Exeter page.

A regulated online pharmacy like nume handles the full process (consultation, clinical review, prescription and dispensing) in one place. Treatment is only dispatched once a GPhC-registered Independent Prescriber has reviewed your consultation; the decision is clinical, not automated. If you would like to explore whether tirzepatide is a good fit for your circumstances, speak to our prescribers through a free consultation via our weight-loss treatments page.